| Patient | Charles Darwin |
|---|---|
| Date of birth | 1986-02-12 |
| Identifiers | MRN HR-NI003-SYN; SSN (made up) 000-03-2967 |
| Document date | 2026-04-14 |
| Author | Bernard Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week follow-up: results, gastroenterology consultation the same day, and a treatment plan. [S]
Mr. Darwin is a 40-year-old man evaluated six weeks ago for more than a year of episodes of nausea and repeated vomiting, who returns for his results and is seen by gastroenterology on the same day. His diary records three episodes since the first visit, each starting in the early morning or after a social evening, with half an hour to an hour of nausea, sweating, trembling hands, a racing heart, and a swimming head, then vomiting many times over 18 to 30 hours. He lay in a dark room and sipped water, and did not need emergency care. Between episodes he has wind and tires by the afternoon but does not vomit. His weight is steady. He confirmed again that he has never used cannabis and does not take long hot baths or showers during episodes. The blood and urine tests and ECG at the first visit were normal, the CT enterography two weeks later was normal, and the upper endoscopy two weeks ago was normal, with normal duodenal biopsies. [S]
| Element | Detail |
|---|---|
| Episodes | Three in six weeks, each 18 to 30 hours, with a half-hour to one-hour prodrome |
| Between episodes | Wind and fatigue; no vomiting |
| Cannabis | Never used; no compulsive hot bathing |
| Results | Blood tests, urinalysis, ECG, CT enterography, and upper endoscopy all normal |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Episodic vomiting; wind between episodes; no blood in vomit or stool; no nocturnal pain |
| Constitutional | Positive | Tired after episodes; weight steady |
| Cardiovascular | Positive | Racing heart only in the prodrome; no chest pain or fainting |
| Neurological | Negative | No migraine headaches, weakness, or visual loss; swimming head only in the prodrome |
| Psychiatric | Positive | Worry about episodes in company; no low mood most days; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amitriptyline 25 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 2026-04-14 to 2026-04-28 | completed | S |
| Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode | One spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a week | Nasal route | 2026-04-14 | active | S |
| Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode | Dissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episode | Oral route | 2026-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-14 | Body height | 183 | cm | S |
| 2026-04-14 | Body weight | 71.4 | kg | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 2026-04-14 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-04-14 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-04-14 | Heart rate | 76 | /min | S |
| 2026-04-14 | Respiratory rate | 14 | /min | S |
| 2026-04-14 | Body temperature | 36.7 | Cel | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
Vital signs recorded on 2026-04-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well between episodes; weight 71.4 kg |
| Cardiovascular | Regular rhythm at 76 per minute; blood pressure 116/72 mmHg, with no drop on standing |
| Abdomen | Soft, non-tender, no distension or succussion splash |
| Neurological | Cranial nerves and gait normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosis | active | provisional | R11.15 | S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory. |
| Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluation | resolved | confirmed | R11.2 | S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Episode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed work | Every visit | Completed today | Three episodes in six weeks, 18 to 30 hours each, none needing emergency care; diary to continue |
| Examination | Rome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50) | At diagnosis and with any change in pattern | Completed today | Criteria met with gastroenterology; no red flags |
| Laboratory | Blood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serology | At diagnosis between episodes; repeat only for an atypical episode | Up to date | All normal six weeks ago, drawn between episodes, including lipase 32 U/L, TSH 1.6, morning cortisol 14.2, and tissue transglutaminase IgA 1.2 with normal total IgA; urine dipstick normal |
| Imaging | Upper endoscopy and small-bowel imaging (CT enterography) | Once at diagnosis | Completed today | CT enterography four weeks ago and upper endoscopy with duodenal biopsies two weeks ago reviewed: both normal |
| Imaging | Gastric emptying study | Not routine; only between episodes when gastroparesis is suspected | Not indicated | No fullness, early satiety, or vomiting between episodes to suggest gastroparesis |
| Medication safety | ECG with QTc on amitriptyline and ondansetron (below 450 ms in men) | Baseline, at about 50 mg during titration, and at the target dose | Up to date | Baseline QTc 412 ms six weeks ago; repeat at about 50 mg and at 75 mg |
| Medication safety | Amitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weight | Each visit on treatment | Completed today | Baseline before amitriptyline: weight 71.4 kg, no constipation, no dizziness on standing |
| Survey | Mood and thoughts of self-harm on a tricyclic (PHQ-9) | Each visit on treatment | Up to date | PHQ-9 6 six weeks ago with item 9 scored 0; no thoughts of self-harm today |
| Survey | Anxiety screen (GAD-7) | At diagnosis, then every three months | Up to date | GAD-7 8 six weeks ago; repeat at three months |
| Medication safety | Abortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limits | Every visit | Completed today | Sumatriptan nasal spray and ondansetron dissolving tablets prescribed today, with timing, the one-repeat limit, and no more than six sprays a week explained |
| Self-management | Individualized emergency department protocol letter | At diagnosis; update with any change in treatment | Completed today | Letter written with gastroenterology: intravenous fluids with dextrose, intravenous ondansetron, lorazepam if needed, a dark quiet room, and sparing use of opioids |
| Self-management | Triggers: sleep, meals, travel, social stress, infections | Every visit | Completed today | Social evenings, travel, short sleep, and long gaps without food identified from the diary |
| Self-management | Cannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome) | At diagnosis and yearly | Completed today | Never used cannabis; no hot-bathing behavior |
| Examination | Comorbidities: migraine, orthostatic and autonomic symptoms, sleep disorders | At diagnosis and yearly | Completed today | No migraine headaches; no dizziness on standing; sleep regular except during episodes |
| Medication safety | Mitochondrial supplements (coenzyme Q10, riboflavin) | Conditional; consider with a partial response | Not indicated | Discussed as a conditional option; he prefers to start with amitriptyline alone and add them only if the response is partial |
| Medication safety | Alternative prophylaxis (topiramate or aprepitant) | Only if amitriptyline fails or is not tolerated | Not indicated | First-line amitriptyline started today |
| Self-management | Relaxation training, meditation, or biofeedback; cognitive behavioral therapy offered | Ongoing | Completed today | Diaphragmatic breathing taught; cognitive behavioral therapy offered |
| Examination | Weight and hydration | Every visit | Completed today | 71.4 kg, steady; well hydrated |
| Referral | Gastroenterology consultation | At diagnosis, then as needed | Completed today | Seen today: Rome IV criteria met, provisional diagnosis, prophylaxis and abortive plan advised |
Goal progress:
Guideline basis: Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019); Anxiety Disorders in Adults: Screening (2023)
Follow-up: Portal messages at two and four weeks for the dose increases. Three-month review with the ECG, diary, and anxiety and mood screens. Next scheduled visit 2026-06-09: three-month review: amitriptyline at target dose, ECG, episode diary, and anxiety screen. [S]